Impedimed Ltd (ASX:IPD)
A$ 0.053 0 (0%) Market Cap: 107.22 Mil Enterprise Value: 83.73 Mil PE Ratio: 0 PB Ratio: 2.65 GF Score: 0/100

ImpediMed Ltd Investor Conference Call Transcript

Oct 19, 2021 / 12:00AM GMT
Release Date Price: A$0.175 (+16.67%)
Operator

Thank you for standing by, and welcome to the ImpediMed Limited PREVENT Trial Results Investor Conference Call. (Operator Instructions) I would now like to hand the conference over to Mr. Richard Carreon, Managing Director and CEO. Please go ahead.

Richard Carreon
ImpediMed Limited - MD, CEO, President & Executive Director

Thanks, Kaley. Welcome, everyone, and thank you for joining us today. We're hosting this call to discuss the results of the PREVENT trial, which were just released to the ASX.

On the call today joining me is Tim Cruickshank, our Chief Financial Officer; and Mike Bassett, our Senior Vice President of Corporate and Strategic Development. At the conclusion of our remarks, we'll be taking questions.

First of all, we are very, very pleased to announce the PREVENT trial successfully met its primary endpoint and reached statistical significance. Now as background, the PREVENT trial is a pivotal study. It's the single largest study ever undertaken in lymphedema, and the PREVENT study is a level I randomized controlled trial to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot